SNIPR Biome Strengthens IP Portfolio with Patent Granted for a Novel CRISPR-Cas System
February 24, 2025 04:40 ET
|
SNIPR BIOME
Grant of a patent on February 26th 2025 by the European Patent Office protecting the newly-discovered and characterised CRISPR-CasS system.
Consumer Genomics Market Size to Hit USD 10.8 Billion by 2032, Growing at a 24.6% CAGR - SNS Insider
January 31, 2025 09:50 ET
|
SNS Insider pvt ltd
Pune, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Global Consumer Genomics Market Size & Growth Analysis: “According to SNS Insider, the global Consumer Genomics Market size was valued at USD 1.5 Billion...
Genotyping Market Size is Expected to Reach USD 70.85 Billion by 2033, Growing at a CAGR of 14.32%: Straits Research
January 22, 2025 10:20 ET
|
Straits Research Private Limited - Garner Insights
New York, United States, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Genotyping involves analyzing DNA sequences to ascertain the genetic makeup of the genotypes of living things, such as people, plants,...
CRISPR-based Gene Editing Market Report 2025, with Company Profiles of the Top 10+ Major Market Players
January 13, 2025 11:45 ET
|
Research and Markets
Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added to ...
ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9
January 13, 2025 09:00 ET
|
ERS Genomics
ERS Genomics (‘ERS’), the CRISPR licensing company, today announces the launch of its Express License platform.
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
January 12, 2025 19:05 ET
|
Caribou Biosciences, Inc.
-- CB-010 GALLOP Phase 1 trial initiated in lupus -- -- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 -- -- CB-010 ANTLER 2L LBCL...
Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 07, 2025 16:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Rachel...
Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer
January 02, 2025 08:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the...
Cell and Gene Therapies Current and Future Landscape 2025-2030
January 02, 2025 05:05 ET
|
Research and Markets
Dublin, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapies - Current and Future Landscape" report has been added to ResearchAndMarkets.com's offering.The global CGT market is expected...
Growth Trends in the CRISPR and Cas Gene Market: Industry Opportunities and Strategies to 2028 & 2033
December 13, 2024 09:27 ET
|
Research and Markets
Dublin, Dec. 13, 2024 (GLOBE NEWSWIRE) -- The "CRISPR and Cas Gene Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering.This report describes and...